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Abstract
Background: Low birth weight followed by accelerated weight gain during early childhood has been associated with
adverse metabolic and cardiovascular outcomes later in life. The aim of this study was to examine the impact of early infant
weight gain on glucose metabolism and cardiovascular risk factors in adolescence and to study if the effect differed
between adolescents born small for gestational age (SGA) vs. appropriate for gestational age (AGA).
Methodology/Principal Findings: Data from 30 SGA and 57 AGA healthy young Danish adolescents were analysed. They
had a mean age of 17.6 years and all were born at term. Data on early infant weight gain from birth to three months as well
as from birth to one year were available in the majority of subjects. In adolescence, glucose metabolism was assessed by a
simplified intravenous glucose tolerance test and body composition was assessed by dual-energy X-ray absorptiometry.
Blood pressures as well as plasma concentrations of triglycerides and cholesterol were measured. Early infant weight gain
from birth to three months was positively associated with the fasting insulin concentration, HOMA-IR, basal lipid levels and
systolic blood pressure at 17 years. There was a differential effect of postnatal weight gain on HOMA-IR in AGA and SGA
participants (P for interaction=0.03). No significant associations were seen between postnatal weight gain and body
composition or parameters of glucose metabolism assessed by the simplified intravenous glucose tolerance test. In
subgroup analysis, all associations with early infant weight gain were absent in the AGA group, but the associations with
basal insulin and HOMA-IR were still present in the SGA group.
Conclusion: This study suggests that accelerated growth during the first three months of life may confer an increased risk of
later metabolic disturbances – particularly of glucose metabolism – in individuals born SGA.
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Introduction
Small size at birth is associated with a range of metabolic diseases
in adulthood, including type 2 diabetes, hypertension, and
dyslipidemia [1,2]. However, controversy exists as to whether
acceleratedgrowthininfancyisdisadvantageous.Somestudieshave
shown that rapid weight gain in the early postnatal period has
adverse consequences for later health [3–6]. Others have reported
that low weightat one year of age or low weight gainin the first year
of life – in some cases followed by accelerated growth during
childhood – can contribute independently to the risk of developing
metabolic and cardiovascular disease later in life [7–11]. Accord-
ingly, different pathways of early growth seem to precede the
development of metabolic disturbances later in life [12,13].
The effect of postnatal growth on later health and disease
depends to a high extent on birth weight. Indeed, rapid postnatal
growth may have adverse effects on later health particularly in
individuals born small for gestational age (SGA)[3,14–17] (i.e.
catch-up growth). Thus, a potential confounder in some of the
studies finding adverse effects of accelerated growth in infancy
may be a lack of correction for catch-up growth elicited by low
birth weight per se. Catch-up growth may be due to the fetus
having escaped an adverse intrauterine environment and may
represent a major adaptive mechanism with independent late
consequences [13]. However, catch-up growth can also reflect a
more trivial result of the general statistical phenomenon
‘regression towards the mean’.
We have previously shown that low birth weight for gestational
age, but not restricted fetal growth in the 3
rd trimester, was
associated with insulin resistance and cardiovascular risk factors in
adolescence [18]. Accordingly, the impact of low birth weight on
metabolic disturbances in adolescence do not seem to be due to
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20595restricted intrauterine growth, but may be related either to factors
operating prior to the third trimester or to postnatal catch-up
growth. The aim of the current study was to examine the impact of
early infant weight gain (from birth to 3 and 12 months) on health
in adolescents born small for gestational age (SGA) and appro-
priate for gestational age (AGA).
Methods
Ethics statement
This study was performed according to the Helsinki II
declaration and was approved by the local ethics committee for
Copenhagen and Frederiksberg (KF 01-229/02 & KF 01-065/03).
Informed consent was obtained from all participants and from the
parents when the participant was under 18 years of age.
Cohort study of fetal and postnatal growth (1985–1987)
In a randomised controlled trial performed in 1985 to 1987 [19],
data were collected on third trimester fetal growth velocity, birth
weight for gestational age and early infant growth in the first year of
life.Birth weightforgestationalageandintrauterine growthvelocity
were used as inclusion criteria for the follow-up at adolescence, and
postnatal growth data were used for the present analyses.
The study design is shown in Figure 1. One thousand pregnant
women were included in the original trial on the basis of one or
more risk factors for giving birth to a SGA child. The list of risk
factors has been reported in detail previously [18]. Ultrasound at
18 weeks was used to establish gestational age, and ultrasound
from 28 weeks was used to estimate fetal weight repeatedly [20].
Fetal growth velocity in the third trimester (FGV) could be
determined in 594 subjects born at term, and was expressed as
change in standard deviation scores (SDS) of fetal weight per 28
days [21] using a sex-specific reference of fetal growth [22]. Birth
weight SDS was calculated using the same growth reference [22].
Intrauterine growth restriction (IUGR) was defined as declining
growth in the third trimester using the cut-off of FGV below the
10
th percentile (20.39 SDS/28 days). SGA was defined as birth
weight SDS below the 10
th percentile (-1.28 SDS), and AGA was
defined as birth weight SDS above this cut-off. The relationships
of FGV and IUGR with insulin resistance and associated
cardiovascular risk factors in adolescence have been published
elsewhere [18].
Follow-up examinations were performed at 3, 6 and 12 months
on half of the cohort [21]. Weight, length, and head circumference
were measured and transformed to SDS using a national chart of
infant growth [23].
Follow-up in adolescence 2003–2005
A total of 547 offspring were traceable, and among these 271
were invited to participate (all those who were SGA or IUGR and a
random sample of AGA/not-IUGR) (Figure 1). The study was
predicted to have the power of 80% to detect a difference in mean
arterial blood pressure of 5 mmHg. One hundred and twenty three
subjects (52 male, 71 female) agreed to participate. Participants and
non-participants did not differ statistically significant concerning
birth weight SDS (20.6361.21 vs. 20.6161.11 SDS)(P=0.88) or
FGV (20.1760.40 vs. 20.1960.38 SDS/28 days)(P=0.78).
Supplementary data (n=27) for the calculation of infant weight
gain from birth to one year was collected by questionnaire. In total,
87 individuals (40% males) had data on weight SDS at three months
and/or at one year and were included in the analyses. Of these, 57
were AGA and 30 were SGA (Figure 1, Table 1). The gender
distribution did not differ significantly between the SGA and AGA
groups (P=0.574). There were no statistically significant differences
in the measured outcomes at follow-up between individuals with
postnatal growth data and those without.
Validated questionnaires [24–26] were used to assess lifestyle
factors of the participants and their parents, as well as breast-
feeding (only breastfeeding exceeding three months was consid-
ered in these analyses).
One subject (AGA) was excluded from all analyses because of a
diagnosis of type 1 diabetes. Polycystic ovary syndrome had
previously been diagnosed in one girl; she was included in the
analyses; exclusion did not alter the results.
Experimental protocol
The experimental protocol has been described in detail
previously [18]. In brief, it included fasting blood sampling, a
simplified intravenous glucose tolerance test (IVGTT) [27], as well
as measures of height (to the nearest 0.1 cm), weight, waist and hip
circumference, fat mass and lean mass by dual x-ray absorptiom-
etry (DXA) and resting systolic and diastolic blood pressure (BP).
Trunk fat was expressed in percentage of total fat mass.
Female participants who did not use oral contraceptives (n=29
of 71) were examined at day 2 to 5 of their menstrual period.
Biochemical analyses
Blood samples for measurement of plasma insulin were
centrifuged immediately at 4uC and stored at 220uC until plasma
insulin concentrations were determined by the AutoDELPHIA
Time-resolved Fluoroimmunoassay (Perkin Elmer-Wallac Oy,
Turku, Finland) (total interassay CV,6%). Plasma glucose
concentration was measured using the Hexinase/G6P-DH-
Determination (Hitachi 912 System; Roche Diagnostics, Hvi-
dovre, Denmark) (intra-assay precision: SD=0.09 mmol/l; inter-
assay precision: SD=0.15 mmol/l). Plasma triacylglycerol and
cholesterol (total, HDL-cholesterol and LDL-cholesterol) were
measured using an enzymatic absorption photometric method
(Roche Modular Analytics [SWA] P-module; Roche Diagnostics)
(CV,5%).
Calculations
Infant weight gain from birth to three months (DWSDSbirth to 3
months) was calculated as ((weight SDS3 months – birth weight SDS)/
(age at measurement))*91 days. Infant weight gain from birth to one
year (DWSDSbirth to 1 year) was calculated as: ((weight SDSone year –
birth weight SDS)/(age at measurement)*365 days. For those who
were not measured at one year in the original trial, we used a
measurement of weight between 11 and 13 months (both months
included), if reported in the questionnaire.
According to the methods described by Galvin et al. [27], and
using thetrapezoidal rule,wecalculated:first-phase insulinresponse
(FPIR) as D insulin area above basal0–10 min divided by D glucose
peak above basal0–10 min, glucose disappearance rate (Kg) (slope of
log glucose concentration10–40 min), and insulin sensitivity (SI) (Kg/D
insulin area above basal0–40 min). Disposition index (DI), represent-
ing insulin secretion corrected for the ambient degree of insulin
resistance, was also calculated (SI6D insulin area0–10min). Further-
more, mean basal glucose (mean of three basal samples), mean basal
insulin (mean of three basal samples) and homeostasis model
assessment of insulin resistance (HOMA-IR) were calculated [28].
Statistical analyses
Dependent variables that did not fulfil the assumption of
normality were logarithmically transformed, which in all cases
gave distributions close to normal. Effects of DWSDSbirth to 3 months
and DWSDSbirth to 1 year on later health were analysed separately.
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Effects of post-natal growth on fat and lean body mass were
adjusted for current weight, and effects of post-natal growth on
blood pressure were adjusted for height and age. Age at
examination and the use of oral contraceptives were not included
in the analyses, because preliminary analyses showed that
Figure 1. Study design. AGA: Appropriate for gestational age. GA: Gestational age. SGA: Small for gestational age. IUGR: Intrauterine growth
restricted. DWSDSbirth to 3 months: Infant weight gain from birth to 3 months. DWSDSbirth to 1 year: Infant weight gain from birth to 1 year.
doi:10.1371/journal.pone.0020595.g001
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adjustments for current BMI, fat mass and fat percentage were
performed, each in separate analyses. Using general linear models
with interaction terms between early infant weight gain and AGA/
SGA status, we determined whether the effects of early infant
weight gain on later health differed significantly between the SGA
and AGA groups. Individuals born AGA and SGA were compared
to each other using Students t-test for the continuous variables and
Chi
2-test for frequencies. All statistical analyses were performed
using the statistical package SPSS (version 14; SPSS, Inc.,
Chicago, IL).
Results
Subject characteristics
Individuals in the SGA group had lower birth weight SDS (in
agreement with the classification), and higher absolute early infant
weight gain from birth to three months and to one year (Table 1).
At one year of age, children born SGA were still considerably
smaller than those born AGA (21.28+/20.94 SDS vs. 20.52+/
20.90). There was an inverse correlation between birth weight
SDS and infant weight gain at both 0–3 months (r=20.67,
P,0.0001; Figure 2A) and 0–12 months (r=20.67, p=
,0.0001). In adolescence, individuals born SGA were shorter,
although slightly older at examination, compared with the AGA
individuals (Table 1). There were no significant differences in
measures of adiposity between the groups.
Effects of early infant weight gain on markers of the
metabolic syndrome
Effects in the entire group. In the entire group,
DWSDSbirth to 3 months was positively associated with basal
insulin concentration and HOMA-IR, as well as with plasma
triglyceride, total cholesterol, LDL, and systolic blood pressure at
adolescence (Table 2). Furthermore, we found a near-significant
inverse association between DWSDSbirth to 3 months and insulin
sensitivity (SI derived from IVGTT) and a near-significant positive
association between DWSDSbirth to 3 months and fat mass (Table 2).
Of the tested variables, DWSDSbirth to 1 year was only positively
associated with HOMA-IR (B=0.13; 95% CI: 0.000 to 0.27)
(P=0.05).
Effects in the SGA and AGA groups. General linear models
showed differential effects of DWSDSbirth to 3 months in the SGA and
AGA on both HOMA-IR (P for interaction=0.03, Figure 2B) and
mean basal glucose concentration (P for interaction=0.04,
Figure 2C). Similarly, the effect of DWSDSbirth to 1 year on
HOMA-IR was significantly different in the SGA and AGA
groups (P for interaction=0.03). In the SGA group, the association
of DWSDSbirth to 3 months with basal insulin levels and HOMA-IR
was positive (Table 2 and Figure 2B). After adjustment for measures
of adiposity in adolescence (BMI, waist-hip ratio, or trunk
fat percentage), the association of early infant weight gain
(DWSDSbirth to 3 months) with HOMA-IR remained significant in
the SGA group (P,0.05). DWSDSbirth to 1 year was also positively
associated with HOMA-IR in the SGA group (P=0.02). In the
AGA group, early infant weight gain from birth to three months
(Table 2) or to one year (data not shown) was not associated with
any of the studied parameters.
Lifestyle and socioeconomic factors. To assess whether
the observed differences between SGA and AGA in this study were
due to differences in lifestyle factors, we compared physical
activity, nutrition, breastfeeding, and smoking habits of the
participants, and in addition we compared employment,
education, health, physical activity and nutrition of the parents
in the SGA and AGA groups with data on postnatal growth.
However, there were no significant differences between the SGA
and AGA group in regard to these parameters, or with regard to
the response rate of the questionnaire (P.0.05 for all; data not
shown).
Discussion
In this prospective study we observed a relationship of early
infant weight gain from birth to three months with glucose
metabolism, lipid profile, fat mass and systolic blood pressure in
adolescence. Interestingly, the associations to glucose metabolism
were only apparent in adolescents born SGA, supporting that
catch-up growth is adversely associated with disturbances of
glucose metabolism later in life, while accelerated weight gain in
infants born AGA does not seem to be particularly detrimental
for glucose metabolism in adolescence. Our finding that early
infant weight gain had different effects on glucose metabolism
but similar effects on lipid profile and blood pressure among the
SGA and AGA groups is novel, and support a growing
awareness of differential trajectories and mechanistic pathways
of the influence of pre- versus post-natal growth on the
development of diabetes, stroke and coronary heart disease
[12]. In other words, adverse effects occurring during different
time points in pregnancy on a distinct metabolic outcome
relevant to the metabolic syndrome may differ from adverse
developmental programming effects occurring after birth and
vice-versa. The exact causes and underlying mechanisms
responsible for our findings of differential effects on glucose
and lipid metabolism remain to be determined. However,
epigenetic mechanisms including DNA methylations may be
involved. For instance, the associations between early infant
weight gain, HOMA-IR and basal insulin in adolescents born
SGA could be explained by higher DNA methylation patterns of
key regulators of glucose metabolism in those born SGA
Table 1. Anthropometry at birth, infancy and adolescence of
subjects born appropriate for gestational age (AGA) and small
for gestational age (SGA).
AGA (n=57) SGA (n=30)
Males (%) 40 40
Birth
Birth weight (g) 35166409 27146284***
Birth weight SDS 0.1760.86 21.8160.42***
Gestational age (days) 27868.8 27769.1
Infancy
DWSDSbirth to 3 months 20.2560.76 0.7860.59***
DWSDSbirth to 1 year 20.7161.11 0.5460.79***
Adolescence
Age at examination (years) 17.560.7 17.960.7*
Height (cm) 172.567.9 167.068.7*
BMI (kg/m
2)2 2 . 9 64.0 22.264.4
Waist-hip ratio 0.7960.05 0.8160.10
Trunk fat (%) 34 [24 to 47] 35 [26 to 48]
Data are means 6 SD or [95% confidence limits] in the AGA and SGA group for
the 87 subjects with data on early infant weight gain. DWSDS = change in
weight SDS. ***P,0.001, *P,0.05.
doi:10.1371/journal.pone.0020595.t001
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showed that young men born SGA had increased DNA
methylation of the promoter region of the key metabolic
regulator peroxisome proliferator-activated receptor gamma,
coactivator 1alpha (PPARGC1A) influencing insulin action in
muscle compared with matched controls born AGA [29].
Furthermore, the men born SGA had a much lower responsive-
ness of DNA methylation to the ‘‘diabetogenic’’ challenge of 5
days of overfeeding compared with men born AGA. This
suggests that growth restriction early in life may lead to a less
dynamic epigenetic flexibility when exposed to environmental
challenges in adulthood. However, the field of epigenetics in
developmental programming is currently at its infancy and much
more studies are needed before it can be concluded whether
DNA methylation plays any role in programming of human
metabolism.
Other studies have shown adverse effects of accelerated early
infant growth on glucose metabolism in infants and children born
SGA. These findings include increased basal insulin levels
associated with growth of weight between birth and one year [6]
or three years [17] of age, and a positive association between linear
growth and insulin secretion during IVGTT at six months [30]
and at one year of age [6]. Leunissen et al. found that rapid growth
during the first 3 months of life was associated with insulin
resistance and markers of cardiovascular disease in young adults
independent of birth weight SDS [31]. In contrast, some
population-based studies have reported that low weight gain
during infancy followed by accelerated weight gain during later
childhood is associated with an increased risk of developing
ischaemic heart disease, type 2 diabetes, and the metabolic
syndrome [7–11]. Hence, the timing of rapid weight gain during
infancy and childhood seems rather important for later develop-
ment of health and disease. Our novel observation that rapid
infant weight gain during the first three months of life causes
adverse effects on glucose metabolism, lipid profile and hyperten-
sion among adolescents born SGA may have been missed in
previous studies for a number of reasons. These include lack of
correction for birth weight, less frequent and/or accurate
determinations of weight during infancy and as well as differences
in accuracy and standardizations of measurements during
adolescence. Other factors such as secular trends and general
living conditions during different time periods may influence the
impact and timing of adverse developmental programming.
Underfeeding of infants and young children was quite common
Table 2. Effects of early infant weight gain (DSDSbirth to 3 months) on glucose metabolism, body composition, and cardiovascular
risk factors at adolescence.
ALL AGA SGA
(n=65) (n=41) (n=24)
Glucose metabolism N
Basal glucose (mmol/l) 58 0.0160.05 20.0660.06 0.2860.14
Kg (10
2 min
21)5 4 20.15 [20.36; 0.08] 20.08 [20.40; 0.29] 20.34 [20.78; 0.26]
Basal insulin (pmol/l) 59 7.33 [2.28; 13.0] *** 2.53 [23.06; 9.09] 18.3 [0.65; 42.4] *
HOMA-IR 57 0.29 [0.10; 0.51] ** 0.07 [20.14; 0.30] 0.99 [0.27; 1.99] **
Insulin sensitivity (10
5 min
21 per pmol l
21 min) 54 20.07 [20.12; 0.002] 20.07 [20.15; 0.04] 20.10 [20.20; 0.07]
First-phase insulin response (pmol l
21 min per mmol l
21) 54 2.04 [24.45; 10.0] 4.65 [25.39; 18.3] 24.73 [215.94; 14.1]
DI (10
5 min21) 54 277.5 [2220; 104] 223.9 [2258; 309] 2224 [2421; 110]
Body composition
Lean body mass (kg)
11 61 20.85 [21.90; 0.22] 20.44 [21.95; 1.12] 0.10 [22.88; 3.18]
Fat mass (kg)
11 61 0.63 [20.03; 1.32] 0.29 [20.56; 1.23] 0.71 [21.33; 3.13]
Trunk fat (%) 61 1.4060.85 1.0861.12 1.9762.53
Waist/Hip ratio 65 0.01 [20.01; 0.03] 0.00 [20.02; 0.02] 0.00 [20.07; 0.08]
Lipid profile
Triacylglycerol (mmol/l) 60 0.15 [0.04; 0.28] ** 0.07[20.07; 0.24] 0.15 [20.17; 0.60]
Cholesterol(mmol/l) 63 0.23 [0.01; 0.48] * 0.15 [20.18; 0.50] 0.44 [20.20; 1.21]
LDL-cholesterol (mmol/l) 62 0.25 [0.04; 0.48] * 0.24 [20.08; 0.60] 0.22 [20.29; 0.85]
HDL-cholesterol (mmol/l) 63 20.03 [20.12; 0.06] 20.05 [20.16; 0.07] 0.17 [20.13; 0.54]
Blood pressure
Systolic BP (mmHg)
1 65 2.6361.30* 20.2061.90 2.8263.23
Diastolic BP (mmHg)
1 65 1.6561.02 1.1461.49 1.1462.90
Data are linear regression coefficients 6 SE or [95% confidence limits]. For the purpose of tabulation the regression coefficients and confidence limits for log-
transformed dependent variables were scaled using the regression coefficient for the untransformed variable. All regressions are adjusted for sex.
1Adjusted for sex, age
and current height.
11Adjusted for sex and current weight. ***P,0.001, **P,0.01, *P,0.05.
doi:10.1371/journal.pone.0020595.t002
Figure 2. Correlations of infant weight gain with birth weight, HOMA-IR and plasma glucose. Correlations between infant weight gain
from birth to 3 months and birth weight SDS (Panel A), HOMA-IR at adolescence (Panel B), and mean basal plasma glucose concentration at
adolescence (Panel C) in individuals born appropriate for gestational age (AGA) and small for gestational age (SGA). *: P,0.005 for association.
doi:10.1371/journal.pone.0020595.g002
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th century, whereas overfeeding has
become more common during recent years. Therefore, it may be
speculated that in cohorts of people born in the 1930–1940’s, the
adverse metabolic programming could potentially occur at a later
time during childhood than in the cohorts born in the 1980–
1990’s.
Adiposity seems to play a major role in the association
between low birth weight, childhood growth and adult disease
[16,32–38]. Therefore, it is noteworthy that measures of
adiposity in adolescence did not differ between the AGA and
SGA groups, nor was accelerated growth during infancy
associated with adiposity in adolescence in our study. This
may be due to the relatively low number of individuals in our
study, since other larger studies have found clear associations of
birth weight and early weight gain with later obesity [36,37].
The European Youth Heart Study [37] recently showed that
higher birth weight was associated with higher fat mass index
and waist circumference in 1,254 9 year-old children and 15
year-old adolescents. Also the ALSPAC study of more than
8,000 7-year-old children [36] provided evidence that birth
weight, weight gain in the first year of life as well as catch-up
growth and other risk factors in early life are associated with
adiposity in childhood. In other studies risk of obesity has also
been positively associated with weight gain in the first week of
life [39], between birth and four months [40], between birth and
two years of life [41], and between ages two and four years [42].
However, only few prospective studies until now have obtained
precise recordings of early infant growth and detailed measure-
ments of later metabolic health. One of them found that infant
weight gain from birth to 6 months was positively associated with
metabolic risk at 17 years of age [3]. No test was performed to
assess whether the associations were similar across birth weight
groups. However, after adjustment for birth weight SDS, the
associations of early infant weight gain with lipids and blood
pressure later in life remained statistically significant and the
association to basal insulin was near-significant [3]. This
supports an independent effect of early infancy weight gain with
adverse cardio-metabolic features later in life. Also in our study,
the associations between early infant weight gain and insulin
resistance in the SGA group remained significant after
adjustment for current BMI, fat mass or fat percentage,
indicating that the effect of early infant weight gain on insulin
resistance goes beyond an effect of predisposition to adiposity.
This finding is in accordance with other studies where the effect
of birth weight on insulin resistance and other metabolic risk
factors in adolescence and adulthood also persisted after
adjustment for current obesity degree [3,43].
Previously, we showed in this cohort of adolescents that being
born SGA was associated with a wide range of markers of the
metabolic syndrome [18]. In the present analyses, we found that
accelerated early infant weight gain from birth to three months
was also associated with markers of the metabolic syndrome:
increased basal insulin levels, HOMA-IR, adverse lipid profile,
and hypertension. The extent to which the impact of growth
during the first year of life was explained by growth during the
first three months could not be assessed, because too few subjects
had data on both variables of early infant weight gain (only 17
SGA subjects). Nevertheless, our results indicate that acceleration
of early infant weight gain may aggravate the effect of low birth
weight on glucose metabolism later in life, and that especially the
first three months after birth represent a critical window. The
notion of a critical window of developmental programming in
humans shortly after birth is indeed supported by animal studies.
Harder et al. infused daily doses of long-acting insulin or saline
from the 8
th to the 11
th day of life in Wistar rats [44]. The
animals receiving insulin infusion developed more obesity, insulin
resistance and glucose intolerance in adulthood, illustrating that
short-term insulin administration during a critical period of
postnatal life has serious long-term consequences for glucose
regulation in rats. In another study, the glucagon-like peptide-1-
receptor agonist Exendin-4 was injected daily from day 1 to day 6
after birth in intrauterine growth-retarded rats [45]. Interestingly,
this short-term infusion of Exendin-4 right after birth reversed the
adverse consequences of fetal undernutrition on glucose metab-
olism later in life. Most strikingly, the rats treated neonatally with
Exendin-4 showed improved glucose tolerance, normalized beta
cell proliferation and even reduced mortality later in life
compared to vehicle-treated intrauterine growth-retarded rats
[45]. Taken together, the studies indicate that it is possible to
induce as well as to protect against dysmetabolic traits by
endocrine manipulations during a critical window right after
birth. Our data suggest that similar mechanisms operate in
humans and that the time period shortly after birth is a window
of opportunity for prevention of later metabolic abnormalities.
However, as already indicated above, there may be other critical
time windows during gestation as well as during postnatal
development where interventions may have similar or even larger
effects on future health and disease.
In a previous publication [18], we showed that fetal growth in
the last trimester does not have an effect on the metabolic
phenotype in adolescence [18]. Hence, the most sensitive period in
fetal life appears to be before the 3
rd trimester. Thus,
paradoxically, growth in the first three months after birth seems
to be more important than growth in the last three months before
birth. This suggests that birth in itself opens a new window of
sensitivity to metabolic programming, perhaps as an adaptive
response to the change of environment. Efforts to alter the
postnatal environment, i.e. to restrict early infant weight gain in
SGA individuals, have hitherto not been recommended. Weight
gain during the first months after birth is influenced both by the
mode of feeding and the amount of energy eaten. A systematic
review has shown that breastfeeding is associated with a reduced
risk of type 2 diabetes later in life [46]. Unfortunately, the quality
of the data on dietary intake during the first three months of life in
our study did not allow an analysis of the potential effects of early
feeding.
In conclusion, we found that accelerated growth during the first
three months of life was associated with later metabolic
disturbances – particularly of glucose metabolism – in individuals
born SGA. Our findings thereby support the idea that the very
early postnatal period is a critical window for individuals who have
experienced a growth insult in fetal life.
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